Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

Contributed by: Business Wire

Logo

Tags

Science

Women

Other Science

Biotechnology

General Health

Health

Medical Devices

Consumer

MIUDELLA, licensing agreement, Sebela Pharmaceuticals

More Like This

Organon Completes Divestiture of JADA® System to Laborie

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Caldera Medical Acquires UVision360 and the LUMINELLE Product Family, Expanding Minimally Invasive Hysteroscopy Portfolio

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

PR Newswire associated0

MedAlliance Acquired by Cordis for up to USD 1.135 Billion